UK drug major GlaxoSmithKline has appointed Thierry Le Chevalier to the post of vice president of its Oncology Medicine Development Center, as well as scientific advisor. Prior to his current position at the French National Cancer Institute, Dr Le Chevalier held a number of jobs at the Institut Gustave Roussy, including as head of its cancer medicine division. He has also previously served as chairman of the Lung Cancer Group of the French Federation of Cancer Centers and of the Scientific Committee of the French Intergroup on Thoracic Oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze